Sodium Polystyrene Sulfonate
Sodium Polystyrene Sulfonate is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Sodium Polystyrene Sulfonate; Generic name: SODIUM POLYSTYRENE SULFONATE; Drug class: Potassium Binder [EPC].
| Brand name | Sodium Polystyrene Sulfonate |
|---|---|
| Generic name | SODIUM POLYSTYRENE SULFONATE |
| Drug class | Potassium Binder [EPC] |
| Manufacturer | CMP Pharma, Inc. |
| Used for | INDICATION AND USAGE SPS ® Suspension is indicated for the treatment of hyperkalemia. |
| Dosage | DOSAGE AND ADMINISTRATION Administer sodium polystyrene sulfonate suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation (see WARNINGS and PRECAUTIONS, Drug Interactions ). The average daily adult dose is 15 g (60 mL) to 60 g (240 mL) of suspension. This is best provided by administering 15 g (60 mL) of SPS ® Suspension one to four times daily. Each 60 mL of SPS ® Suspension contains 1500 mg (65 mEq) of sodium. Sinc |
| Warnings | WARNINGS Intestinal Necrosis Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with sodium polystyrene sulfonate use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency a |
| Active ingredient(s) | SODIUM POLYSTYRENE SULFONATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d48dcf-07bd-4b06-bd6c-7543f1be8357 |